TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02295826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
Study: NCT02183883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.~EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade \> 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg.
Study: NCT03397498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogniFit™
Description: The program utilizes 21 tasks, which may develop 14 cognitive domains: awareness, inhibition, spatial perception, visual short term memory, working memory, hand-eye coordination, visual scanning, response time, divided attention, time estimation, visual perception, shifting, naming, and planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control-games
Description: The program utilizes classic computer games, which may develop cognitive domains. Games will be used over 8 weeks. The participants will use the program 3 days a week, with one rest day between each session. Each session lasts approximately 20 minutes. The participant will use the program for a total number of 24 sessions.
Study: NCT03309943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one dose of Placebo on two separate occasions.
Study: NCT02596204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly Review
Description: Subjects will wear a FitBit activity monitor and continue to use their insulin pump. Fitbit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (CDE, NP and/or MD) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit
Description: All subjects will wear a FitBit activity monitor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: All subjects will wear a FitBit activity monitor.
Study: NCT03454308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMASH
Description: Auditory and visual reminders are active on Pill device will alert subject each time their medication dose is due. Pill device will transmit dose taken time stamps to researchers. Text message the following morning with tailored motivational messages that reflect the medication dose adherence from the preceding day. Subjects will monitor their BP at home at least every third day using Bluetooth monitor linked to smartphone to transmit encrypted readings to researchers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced SC
Description: Auditory and visual reminders are inactive on Pill device. Pill device will transmit dose taken times to researchers. Healthy lifestyle test messages as attention control.
Study: NCT01664052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS505 (Essure, BAY1454033)
Description: Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
Study: NCT03825029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pillow
Description: A pillow to lessen the angle differences between hips so that the acetabular component can be placed in an optimal position.
Study: NCT03677284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time assistive products
Description: The decision on the specific time assistive product to be prescribed will be decided based on current knowledge and the personal goal of the PwD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information brochure
Description: The information brochure will provide information frequent problems about daily time management and suggest strategies to manage them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information brochure
Description: The information brochure will provide information frequent problems about daily time management and suggest strategies to manage them.
Study: NCT03721874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered dapagliflozin 10 mg during Period 1 or Period 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to Dapagliflozin 10 mg
Description: The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered placebo during Period 1 or Period 2.
Study: NCT03999151

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Diet
Description: Behavioral program provides access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Diet
Description: Behavioral program provides access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D)
Study: NCT01664052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS305 (Essure, BAY1454032)
Description: Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
Study: NCT03999151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Diet
Description: Behavioral program provides access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Diet
Description: Behavioral program provides access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D)
Study: NCT01664052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS505-A (Essure, BAY1454033)
Description: Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
Study: NCT05676606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote 1-minute single-lead electrocardiogram (ECG) monitoring in cancer patients after the first polychemotherapy cycle.
Description: Recording of the ECG using smart-phone at rest, 15 minutes before registering ECG patient should not smoke,having tea, coffee, alcohol. During the ECG recording hands should be fixed to avoid poor quality. Patient sitting on a char with tow hands fixed on a table holding electrocardiograph with index fingers placed at the ECG electrode (left) and at the photoplethysmograph sensor(right).ECG signals are recorded from the fingers using first standard ECG lead. After registration, all ECG and photoplethysmography data will be sent to the server. The data will be automatically compared with a standard for data quality, after that the data will be sent to cardiologist. If quality will be not sufficient, the data will be deleted and the doctor will contact the patient to solve the quality issue. Thereafter, the parameters will be carried out by cardiologist, on the basis of which value of ECG monitoring will be estimated.
Study: NCT03784742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate rich beetroot juice
Description: James White Drinks Limited beetroot juice (0.4-0.45 g nitrate/70 ml drink).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beetroot juice
Description: James White Drinks Limited Placebo beetroot juice (0 nitrate/70 ml drink).
Study: NCT00611923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
Study: NCT00679211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla]
Description: Intravenous repeating dose
Study: NCT02199236

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: endorectal brachytherapy
Description: Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent capecitabine or 5-FU
Description: Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
Study: NCT01369251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hygiene

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual alcohol care
Study: NCT01084005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: patients receive linagliptin 5 mg tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients receive placebo matching linagliptin 5 mg once daily
Study: NCT03107351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac contractility assessments with Kino-cardiograph
Description: Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cardiac assessment repeatability with Kino-cardiograph
Description: Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
Study: NCT01810796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine versus placebo
Study: NCT01823445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol disk
Study: NCT02742181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: Subjects diagnosed with a post operative ileus after surgery will be given alvimopan

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Standard postoperative care
Study: NCT03091530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleeper Stretch
Description: The sleeper stretch protocol will follow the process described by Wilk with the subject lying on his throwing shoulder side, with the lateral border of the scapula on the table, and the glenohumeral and elbow joints both at 90 degrees of flexion. Participants will be instructed to passively internally rotate the shoulder with gentle overpressure applied on the dorsum of the dominant arm wrist by the nondominant hand to the point of stretch on the posterior aspect of the shoulder. Stretches will be held for 20 seconds each and repeated 4 times for optimal sustained collagen elongation. This protocol will be performed on days 0-4 after the throwing session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleeper Stretch
Description: The sleeper stretch protocol will follow the process described by Wilk with the subject lying on his throwing shoulder side, with the lateral border of the scapula on the table, and the glenohumeral and elbow joints both at 90 degrees of flexion. Participants will be instructed to passively internally rotate the shoulder with gentle overpressure applied on the dorsum of the dominant arm wrist by the nondominant hand to the point of stretch on the posterior aspect of the shoulder. Stretches will be held for 20 seconds each and repeated 4 times for optimal sustained collagen elongation. This protocol will be performed on days 0-4 after the throwing session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 90/90 Hip Lift with Balloon Blow Exercise
Description: The 90/90 Hip Lift with Balloon Blow Exercise (BBE) will follow the guidelines described by the Postural Restoration Institute. The subjects will lie supine with hips and knees flexed to 90 degrees, the right arm flexed to end range and resting on the floor. Using the left arm to hold the balloon, subjects will inhale fully and exhale into a balloon while holding a posterior pelvic tilt. The subjects inhale and then exhale into the balloon fully, then hold their breath for 5 seconds while putting their tongue on the roof of their mouth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 90/90 Hip Lift with Balloon Blow Exercise
Description: The 90/90 Hip Lift with Balloon Blow Exercise (BBE) will follow the guidelines described by the Postural Restoration Institute. The subjects will lie supine with hips and knees flexed to 90 degrees, the right arm flexed to end range and resting on the floor. Using the left arm to hold the balloon, subjects will inhale fully and exhale into a balloon while holding a posterior pelvic tilt. The subjects inhale and then exhale into the balloon fully, then hold their breath for 5 seconds while putting their tongue on the roof of their mouth.
Study: NCT01078623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg / formoterol 12 μg
Description: Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 μg
Description: Formoterol fumarate 12 μg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Description: Aclidinium bromide 200 μg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg / Formoterol 6 μg
Description: Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
Study: NCT00502541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide
Description: fluocinolone acetonide 0.59 mg intravitreal implant
Study: NCT03690128

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-EWS with incorporated clinical assessment (Trigger Tool)
Description: In relation to systematic measurement of vital parameters the nursing staff will perform an individual clinical assessment of the patient and adjust the I-EWS score accordingly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard EWS - Control (Trigger Tool)
Description: Standard EWS - Based on principles of National Early Warning Score (NEWS)
Study: NCT01626196

Intervention type: OTHER
Intervention: No intervention
Description: This was an observational study
Study: NCT02617160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Logic Pump Advisor
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
Study: NCT02391415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: Tuberculosis vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: Tuberculosis vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: commercially available live vaccine BCG

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: commercially available live vaccine BCG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002(Hyg+)
Description: Tuberculosis vaccine
Study: NCT00915018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
Study: NCT01510301

Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)
Description: To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;~* Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;~* Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence.
Study: NCT00698672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: charnley OGEE
Description: charnley OGEE

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectron Reflection CoCr
Description: Spectron Reflection CoCr

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectron XLPE CoCr
Description: Spectron XLPE CoCr

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectron Reflection Oxinium
Description: Spectron Reflection Oxinium

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectron XLPE CoCR
Description: Spectron XLPE CoCR
Study: NCT01014169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Note taking
Description: The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.